Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer

Status:
Completed

Trial end date:
2008-06-01

Target enrollment:

Participant gender:

The purpose of this study is to evaluate the objective tumor response rate to SNS-595 in patients with small cell lung cancer (SCLC).

Phase 2

Sunesis Pharmaceuticals